Zobrazeno 1 - 10
of 115
pro vyhledávání: '"S. Aubrey Stoch"'
Autor:
Marian Iwamoto, Kelly E. Duncan, Prachi K. Wickremasingha, Tian Zhao, Maria V. Liberti, Lieselotte Lemoine, Tatjana Decaesteker, Sylvie Rottey, Brian M. Maas, Gillian Gillespie, S. Aubrey Stoch
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 10, Pp 1947-1956 (2023)
Abstract Molnupiravir is an orally administered, small‐molecule ribonucleoside prodrug of β‐D‐N4‐hydroxycytidine (NHC) that has demonstrated potent, broad‐spectrum preclinical activity against RNA viruses and has a high barrier to the deve
Externí odkaz:
https://doaj.org/article/f55f7be76e6247dbb0db33febe23a640
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 1, Pp n/a-n/a (2024)
Abstract Phase I trials inform on the initial safety profile of a new molecule and impact whether further development is pursued or not. Understanding the effect of non‐pharmacological factors on the variability of routine safety parameters could i
Externí odkaz:
https://doaj.org/article/60784f8b691e4424a7b3470869b534a3
Autor:
Jonathan A. Robbins, Dereck Tait, Qinlei Huang, Sheri Dubey, Tami Crumley, Josee Cote, Julie Luk, Jeffrey R. Sachs, Kathryn Rutkowski, Harriet Park, Robert Schwab, William Joseph Howitt, Juan Carlos Rondon, Martha Hernandez-Illas, Terry O'Reilly, William Smith, Jakub Simon, Cathy Hardalo, Xuemei Zhao, Richard Wnek, Alethea Cope, Eseng Lai, Paula Annunziato, Dalya Guris, S. Aubrey Stoch
Publikováno v:
EBioMedicine, Vol 82, Iss , Pp 104138- (2022)
Summary: Background: Vaccines against COVID-19 are needed to overcome challenges associated with mitigating the global pandemic. We report the safety and immunogenicity of V590, a live recombinant vesicular stomatitis virus-based COVID-19 vaccine can
Externí odkaz:
https://doaj.org/article/a44da410c7ec4f96838eaf6361e76d18
Autor:
Jesse C. Nussbaum, Azher Hussain, Bennett Ma, K. Chris Min, Qing Chen, Charles Tomek, Marian Iwamoto, S. Aubrey Stoch
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 1, Pp n/a-n/a (2022)
Abstract Gefapixant (MK‐7264) is a first‐in‐class, selective antagonist of the P2X3 purinergic receptor currently being investigated as a therapeutic agent for the treatment of refractory or unexplained chronic cough. In non‐clinical studies,
Externí odkaz:
https://doaj.org/article/3048c0862a0e4bedbda92a81a340d0d0
Autor:
Frédéric Vanhoutte, Wen Liu, Richard T. Wiedmann, Liesbeth Haspeslagh, Xin Cao, Keith Boundy, Antonios Aliprantis, Michelle Davila, Jonathan Hartzel, Jianing Li, Mac McGuire, Katrin Ramsauer, Yvonne Tomberger, Roland Tschismarov, Deborah D. Brown, Weifeng Xu, Jeffrey R. Sachs, Kevin Russell, S. Aubrey Stoch, Eseng Lai
Publikováno v:
EBioMedicine, Vol 75, Iss , Pp 103811- (2022)
Summary: Background: We report on the safety and immunogenicity of V591, a measles vector-based SARS-CoV-2 vaccine candidate. Methods: In this multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial, healthy adults with no history
Externí odkaz:
https://doaj.org/article/d59aa9653c964fe6ac6e01ea17db7d32
Autor:
Brian M. Maas, Jos Lommerse, Nele Plock, Radha A. Railkar, S.Y. Amy Cheung, Luzelena Caro, Jingxian Chen, Wen Liu, Ying Zhang, Qinlei Huang, Wei Gao, Li Qin, Jie Meng, Han Witjes, Emilie Schindler, Benjamin Guiastrennec, Francesco Bellanti, Daniel S. Spellman, Brad Roadcap, Mariya Kalinova, Juin Fok-Seang, Andrew P. Catchpole, Amy S. Espeseth, S. Aubrey Stoch, Eseng Lai, Kalpit A. Vora, Antonios O. Aliprantis, Jeffrey R. Sachs
Publikováno v:
EBioMedicine, Vol 73, Iss , Pp 103651- (2021)
Background: Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validat
Externí odkaz:
https://doaj.org/article/29110f874edd46dea00e331b42ac8484
Autor:
Jesse C. Nussbaum, Azher Hussain, K. Chris Min, Thomas C. Marbury, Kenneth Lasseter, S. Aubrey Stoch, Marian Iwamoto
Publikováno v:
The Journal of Clinical Pharmacology. 62:1435-1444
Gefapixant, a P2X3 receptor antagonist, has demonstrated efficacy in patients with refractory or unexplained chronic cough. We investigated the effect of renal impairment (RI) on the pharmacokinetics (PK) of gefapixant 50 mg in an open-label, single-
Autor:
Douglas G. Johns, Louis-Charles Campeau, Puja Banka, An Bautmans, Tjerk Bueters, Elisabetta Bianchi, Danila Branca, Paul G. Bulger, Inne Crevecoeur, Fa-Xiang Ding, Robert M. Garbaccio, Erik D. Guetschow, Yan Guo, Sookhee N. Ha, Jennifer M. Johnston, Hubert Josien, Eunkyung A. Kauh, Kenneth A. Koeplinger, Jeffrey T. Kuethe, Eseng Lai, Christine L. Lanning, Anita Y.H. Lee, Li Li, Anilkumar G. Nair, Edward A. O’Neill, S. Aubrey Stoch, David A. Thaisrivongs, Thomas J. Tucker, Petr Vachal, Kristien van Dyck, Frederic P. Vanhoutte, Bram Volckaert, Dennis G. Wolford, Andy Xu, Tian Zhao, Dan Zhou, Susan Zhou, Xiaohong Zhu, Hratch J. Zokian, Abbas Walji, Harold B. Wood
Publikováno v:
Circulation.
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:835-839
Use of early predictive biomarkers of neurodegenerative disease in phase I clinical trials may improve the translation of novel drug therapies from preclinical development through late-stage studies. This article provides a categorical summary of pro
Autor:
Kazuhiko, Asari, Mikio, Ishii, Hiroyuki, Yoshitsugu, Akira, Wakana, Craig, Fancourt, Esther, Yoon, Kenichi, Furihata, Jacqueline B, McCrea, S Aubrey, Stoch, Marian, Iwamoto
Publikováno v:
Clinical Pharmacology in Drug Development. 11:938-948
Letermovir is a human cytomegalovirus terminase inhibitor for the prophylaxis of cytomegalovirus infection and disease in allogeneic hematopoietic stem cell transplant recipients. The pharmacokinetics, safety, and tolerability of letermovir were asse